Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2024.08.30
Z6尊龙:2024年半年度报告摘要
2024.07.12
Z6尊龙:2024年半年度业绩预告
2024.04.30
Z6尊龙:关于续聘会计师事务所的通告
2024.04.30
Z6尊龙:关于2023年年度股东大会增添暂时提案暨股东大会增补通知的通告
2024.04.30
Z6尊龙:董事会决议通告
2024.04.30
Z6尊龙:关于举行2023年年度业绩说明会的通告
2024.04.02
Z6尊龙:关于依诺肝素钠制剂获得泰国药品注册批件的通告
2024.03.29
Z6尊龙:未来三年(2024年-2026年)股东回报妄想
2024.03.29
Z6尊龙:商誉减值测试报告
2024.03.29
Z6尊龙:关于依诺肝素钠制剂获得新西兰药品注册批件的通告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】